Bindumadhav Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 07-01-2025
- Paid Up Capital ₹ 0.10 M
as on 07-01-2025
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 2.50 M
as on 07-01-2025
- Revenue 334.29%
(FY 2020)
- Profit -34.63%
(FY 2020)
- Ebitda -79.07%
(FY 2020)
- Net Worth -131.51%
(FY 2020)
- Total Assets 162.75%
(FY 2020)
About Bindumadhav Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.50 M.
Anuradha Neurekar and Adhiraj Neurekar serve as directors at the Company.
- CIN/LLPIN
U33110GA2015PTC007638
- Company No.
007638
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2015
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Goa
Industry
Company Details
- Location
Goa, Goa, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bindumadhav Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anuradha Neurekar  | Director | 24-Apr-2015 | Current |
| Adhiraj Neurekar | Director | 24-Apr-2015 | Current |
Financial Performance of Bindumadhav Pharma.
Bindumadhav Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 334.29% increase. The company also saw a substantial fall in profitability, with a 34.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 131.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bindumadhav Pharma?
In 2019, Bindumadhav Pharma had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Electromax Engineering Private LimitedActive 4 years 6 monthsAnuradha Neurekar and Adhiraj Neurekar are mutual person
- De'source Pharma Private LimitedActive 6 years 3 months
Anuradha Neurekar and Adhiraj Neurekar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 Aug 2024 | ₹2.50 M | Open |
How Many Employees Work at Bindumadhav Pharma?
Bindumadhav Pharma has a workforce of 28 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bindumadhav Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bindumadhav Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
